Symptom Severity and Exclusion From Antidepressant Efficacy Trials
- 1 December 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 22 (6) , 610-614
- https://doi.org/10.1097/00004714-200212000-00011
Abstract
It is the standard practice in antidepressant efficacy trials (AETs) to exclude potential participants with major depressive disorder (MDD) who score below a threshold on the Hamilton Rating Scale for Depression (HAM-D). It is unknown to what extent various cutoff scores impact on the generalizability of these trials. In the present report, we sought to determine how many patients with MDD presenting to an outpatient practice would fail to qualify for an AET because their symptoms were not sufficiently severe, and to what extent the variability in HAM-D cutoff scores impacts exclusion rates. Fifteen hundred individuals presenting for an intake at a psychiatric outpatient practice underwent an evaluation with semistructured diagnostic interviews. Five hundred and three patients received a principal diagnosis of nonbipolar, nonpsychotic MDD. Thirty-nine AETs published in five leading journals during the past 7 years were reviewed, 36 of which required a minimum score on the HAM-D for inclusion. We applied the HAM-D cutoffs used in these AETs to the 503 depressed patients to determine how many would qualify for each AET. Based on the least and most restrictive cutoff scores, between 11.3% and 71.0% of the depressed patients from our practice had an insufficient HAM-D score to qualify for an AET. The two most commonly used cutoff scores would lead to the exclusion of almost half of our sample. AETs tend to include the subset of depressed individuals with moderate to severe MDD and exclude a significant proportion of depressed patients who have mild MDD. The implications of these findings are discussed.Keywords
This publication has 43 references indexed in Scilit:
- The Treatment of Chronic Depression, Part 2The Journal of Clinical Psychiatry, 1998
- Once-Versus Twice-Daily Venlafaxine Therapy in Major DepressionThe Journal of Clinical Psychiatry, 1998
- Efficacy and Tolerability of Once-Daily Venlafaxine Extended Release (XR) in Outpatients With Major DepressionThe Journal of Clinical Psychiatry, 1997
- Desipramine Versus Phenelzine in Recurrent Unipolar DepressionJournal of Clinical Psychopharmacology, 1997
- A Comparison of Fluvoxamine and Fluoxetine in the Treatment of Major DepressionJournal of Clinical Psychopharmacology, 1996
- Zalospirone in Major DepressionJournal of Clinical Psychopharmacology, 1996
- A Comparison of Descriptive Variables for Clinical Patients and Symptomatic Volunteers With Depressive DisordersJournal of Clinical Psychopharmacology, 1996
- Severity of depression and response to fluoxetineInternational Clinical Psychopharmacology, 1993
- Consensus Conference on the Methodology of Clinical Trials of Antidepressants, Zurich, march 1988: Report of the Consensus CommitteePharmacopsychiatry, 1989